Quick Takeaways:
- Medgene launched the first and only US prescription platform vaccine targeting Theileria orientalis Ikeda in cattle. The tick-borne parasite causes bovine infectious anemia, fever, jaundice, lethargy, reduced milk production, abortion and death, with USDA data indicating mortality rates of up to 50% in infected cattle.
- Theileria can infect calves, pregnant heifers and cows, and surviving cattle may remain infected for life. There is currently no approved US treatment. Asian longhorned ticks can spread the parasite, while an infected tick may survive in a pasture for up to 2 years. US tick-borne pathogens cause over $13.9B in losses annually.
- Medgene’s vaccine targets both the sporozoite and merozoite stages of the parasite’s lifecycle and is administered as a two-shot series: an initial dose followed by a booster. The vaccine is available by veterinarian prescription, although potency and efficacy of prescription platform biologics have not been established.
Why It Matters?
Medgene’s launch could be a meaningful de-risking event for cattle producers because it creates the first U.S. prescription vaccine option for a parasite with severe herd-level consequences and no approved treatment, potentially reducing losses from mortality, milk declines, abortions, and chronic infection. The market impact is likely to be strongest in regions where Asian longhorned ticks and Theileria risk are already established, since producer adoption would depend on veterinary diagnosis, herd management practices, and confidence in real-world protection. Because it is a prescription platform biologic, uptake may start in higher-risk herds first, and the biggest upside would come if veterinarians view it as a practical way to limit production losses and reduce the need to manage chronic infected carriers.
Source: PRnewswire
